Nvidia exited its positions in several AI stocks in Q4, but maintained its stake in Recursion Pharmaceuticals. Many investors seemed to view this as a vote of confidence from Nvidia for Recursion.

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) had soared by 15.8% as of 12:06 p.m. ET on Friday. Did the clinical-stage biotech company report great news? Nope. Instead, the stock's gains ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Answering SPJA queries under differential privacy (DP), including graph-pattern counting under node-DP as an important ...

In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes through) become one company, combining Recursion’s expertise in biology with Exscientia’s focus on chemistry.

ESET researchers have observed a cluster of North Korea-aligned activities that they named DeceptiveDevelopment and where its ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Friday's market has seen significant movements in a range of stocks, with some experiencing sharp increases while others face ...

After hours: February 19 at 4:05:05 PM EST Loading Chart for PRO ...

After hours: February 19 at 6:15:42 PM EST Loading Chart for TTMI ...